| Quarterly Financials | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 419 | 368 | 440 | 372 | 491 | 345 | 440 | 446 | 468 | 455 | 447 | 441 | 631 | 509 | 456 | 528 | 533 | 483 | 454 | 478 | 535 | 561 | 469 | 581 | 573 | 546 | 623 | 646 | 625 | 730 | 595 | 657 | 662 | 525 | 796 | 690 | 724 |
| Expenses | 318 | 271 | 321 | 263 | 388 | 270 | 311 | 339 | 330 | 362 | 319 | 346 | 480 | 403 | 322 | 417 | 405 | 431 | 359 | 406 | 463 | 450 | 362 | 453 | 559 | 452 | 535 | 529 | 613 | 602 | 529 | 610 | 595 | 500 | 645 | 542 | 575 |
| EBITDA | 101 | 97 | 118 | 109 | 103 | 75 | 129 | 107 | 138 | 93 | 128 | 95 | 151 | 107 | 135 | 111 | 128 | 52 | 95 | 72 | 72 | 111 | 106 | 129 | 14 | 94 | 88 | 118 | 13 | 128 | 66 | 47 | 67 | 25 | 151 | 148 | 149 |
| Operating Profit % | 22 % | 25 % | 25 % | 26 % | 20 % | 20 % | 28 % | 21 % | 27 % | 19 % | 26 % | 19 % | 21 % | 20 % | 29 % | 20 % | 21 % | 9 % | 18 % | 13 % | 12 % | 18 % | 21 % | 19 % | 2 % | 16 % | 13 % | 17 % | 1 % | 17 % | 10 % | 6 % | 9 % | 4 % | 18 % | 21 % | 20 % |
| Depreciation | 30 | 51 | 55 | 51 | 57 | 51 | 55 | 55 | 51 | 54 | 58 | 58 | 71 | 67 | 70 | 72 | 74 | 74 | 78 | 79 | 77 | 75 | 74 | 75 | 84 | 75 | 80 | 50 | 76 | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 |
| Interest | 21 | 23 | 20 | 13 | 10 | 11 | 13 | 13 | 11 | 15 | 15 | 14 | 13 | 14 | 17 | 11 | 20 | 12 | 13 | 14 | 9 | 12 | 14 | 15 | 16 | 19 | 20 | 22 | 24 | 29 | 28 | 33 | 31 | 32 | 37 | 49 | 42 |
| Profit Before Tax | 67 | 36 | 51 | 50 | 83 | 14 | 74 | 68 | 75 | 58 | 71 | 75 | 106 | 46 | 65 | 51 | 35 | -34 | 4 | -22 | -14 | 24 | 19 | 39 | -85 | -0 | -12 | 46 | -88 | 30 | -36 | -66 | -49 | -78 | 42 | 27 | 28 |
| Tax | 17 | 6 | 13 | 17 | 40 | 1 | 26 | 26 | 24 | 18 | 27 | 23 | 30 | 12 | 24 | 18 | -15 | -12 | -3 | -6 | 121 | 8 | 7 | 3 | -41 | -4 | -2 | -1 | -17 | 13 | 5 | -7 | 21 | 0 | 9 | 22 | -15 |
| Net Profit | 50 | 30 | 38 | 33 | 43 | 13 | 48 | 42 | 51 | 40 | 44 | 51 | 76 | 34 | 41 | 33 | 50 | -21 | 7 | -16 | -135 | 16 | 11 | 35 | -45 | 4 | -10 | 47 | -71 | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 |
| EPS in ₹ | 6.17 | 1.88 | 2.37 | 2.01 | 2.65 | 0.81 | 3.00 | 2.60 | 3.17 | 2.46 | 2.73 | 3.18 | 4.70 | 2.13 | 2.55 | 2.04 | 3.11 | -1.37 | 0.47 | -1.02 | -8.61 | 1.02 | 0.71 | 2.26 | -2.85 | 0.26 | -0.64 | 3.00 | -4.51 | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 |
Dishman Carbogen Amcis
263.36
-4.03
(-1.51%)
Company has added their latest Transcript14 hours ago
View
Market Cap
4,129.04 Cr
EPS
-9.79
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
307.98
52 Week Low
133.00
PB Ratio
0.72
Debt to Equity
0.40
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,686.20 | #1 4,04,575.86 | 34.84 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 38.78 | |
6,627.00 | 1,75,926.03 | 80.39 | 8,184.00 | 0.89 | 1,600 | 23.05 | 64.74 | |
1,470.40 | 1,18,751.70 | 22.50 | 26,520.70 | 14.17 | 4,155 | 30.28 | 44.52 | |
3,167.00 | 1,07,185.67 | 55.51 | 10,785.70 | 11.59 | 1,656 | 10.91 | 43.23 | |
1,248.40 | 1,04,173.41 | #1 18.35 | 28,905.40 | 12.36 | 5,578 | 21.14 | 65.27 | |
2,446.80 | 1,00,949.71 | 51.58 | 10,615.60 | 19.57 | 1,942 | -10.91 | 50.67 | |
925.20 | 93,096.77 | 19.93 | 19,831.50 | 13.82 | 3,831 | -0.19 | 61.91 | |
1,953.00 | 89,162.45 | 27.02 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 40.27 | |
1,163.60 | 67,582.08 | 19.30 | 29,559.20 | 17.55 | 3,169 | -0.50 | 41.95 | |
30,215.00 | 64,204.77 | 45.31 | 6,097.20 | 10.80 | 1,201 | 27.83 | 46.13 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
8.33 %
Net Income Growth
415.10 %
Cash Flow Change
44.37 %
ROE
435.29 %
ROCE
-107.32 %
EBITDA Margin (Avg.)
-19.32 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 6,593 | 7,177 | 7,329 | 8,200 | 8,366 | 8,638 | 9,454 | 9,581 |
| Fixed Assets | 4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,188 | 6,724 |
| Current Assets | 1,245 | 1,546 | 1,554 | 1,779 | 1,704 | 1,839 | 1,918 | 1,928 |
| Capital Work in Progress | 133 | 151 | 175 | 234 | 486 | 780 | 1,043 | 646 |
| Investments | 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 |
| Other Assets | 1,569 | 1,764 | 1,889 | 2,097 | 2,010 | 1,761 | 1,973 | 2,109 |
| Total Liabilities | 6,593 | 7,177 | 7,329 | 8,200 | 8,366 | 8,638 | 9,454 | 9,581 |
| Current Liabilities | 994 | 1,178 | 1,198 | 1,569 | 1,290 | 1,420 | 1,798 | 2,555 |
| Non Current Liabilities | 786 | 891 | 751 | 916 | 1,377 | 1,669 | 1,845 | 1,399 |
| Total Equity | 4,814 | 5,107 | 5,379 | 5,715 | 5,699 | 5,549 | 5,810 | 5,628 |
| Reserve & Surplus | 4,814 | 5,075 | 5,347 | 5,684 | 5,668 | 5,518 | 5,778 | 5,596 |
| Share Capital | 0 | 32 | 32 | 31 | 31 | 31 | 31 | 31 |
Cash Flow
| Cash Flow | 2011 | 2012 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -3 | -19 | 59 | 7 | 11 | 46 | 122 | -133 | 22 | 132 |
| Investing Activities | -231 | -104 | -107 | -297 | -169 | -442 | -380 | -619 | -494 | -230 |
| Operating Activities | 203 | 154 | 303 | 226 | 282 | 585 | 513 | 355 | 266 | 384 |
| Financing Activities | 26 | -68 | -137 | 78 | -102 | -98 | -11 | 130 | 250 | -22 |
Share Holding
| % Holding | Apr 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 63.17 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % | 59.32 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.80 % | 8.61 % | 8.70 % | 8.04 % | 8.17 % | 8.74 % | 9.49 % |
| DIIs | 12.80 % | 8.85 % | 6.66 % | 6.05 % | 6.18 % | 6.75 % | 6.54 % | 4.28 % | 3.87 % | 2.56 % | 3.14 % | 3.52 % | 3.69 % | 2.37 % | 1.48 % | 1.23 % | 1.42 % | 1.26 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.93 % | 21.60 % | 22.62 % | 24.75 % | 24.20 % | 23.55 % | 23.73 % | 25.85 % | 25.66 % | 24.61 % | 24.57 % | 24.64 % | 24.54 % | 25.17 % | 27.10 % | 27.43 % | 26.22 % | 25.31 % |
| Others | 13.09 % | 10.24 % | 11.40 % | 9.87 % | 10.30 % | 10.37 % | 10.42 % | 10.55 % | 11.15 % | 13.50 % | 12.97 % | 3.72 % | 3.85 % | 4.45 % | 4.06 % | 3.85 % | 4.29 % | 4.62 % |
| No of Share Holders | 43,186 | 58,738 | 54,077 | 60,726 | 54,662 | 56,322 | 56,986 | 59,654 | 61,175 | 56,583 | 56,221 | 56,272 | 52,336 | 50,656 | 53,683 | 55,280 | 52,822 | 50,757 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1.2 | 0.00 | 0.2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.37 | 0.00 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 May 2025 |  Quarterly Result Announcement | NA | 21 May 2025 | 215.61 | 217.70 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 245.13 | 231.09 |
| 13 Nov 2024 | Quarterly Result Announcement | NA | 13 Nov 2024 | 195.15 | 190.25 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 192.21 | 183.00 |
| 27 Mar 2017 |  Change Of Name | NA | 27 Mar 2017 | 0.00 | 0.00 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 hours ago
14 hours agoAnnouncement under Regulation 30 (LODR)-Demise1 day ago
1 day agoNEWS PAPER ADVERTISEMENT - Postal Ballot Notice And E-Voting Instructions2 days ago
2 days agoShareholder Meeting / Postal Ballot-Notice of Postal Ballot5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation6 days ago
6 days agoAppointment Of Secretarial Auditor7 days ago
7 days agoBoard Meeting Outcome for OUTCOME OF BOARD MEETING ALONGWITH AUDITED FINANCIAL RESULTS ALONGWITH STATUTORY AUDITORS AUDIT REPORT (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31/03/20257 days ago
7 days agoOUTCOME OF BOARD MEETING ALONGWITH AUDITED FINANCIAL RESULTS ALONGWITH STATUTORY AUDITORS AUDIT REPORT (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31/03/20257 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoBoard Meeting Intimation for Considering Take On Record And Approve The Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March 2025May 16, 2025
May 16, 2025DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015 : AMENDMENT IN TERMS RELATED TO FINANCIAL COVENANTS IN RESPECT OF NON-CONVERTIBLE DEBENTURES (Ncds) ISSUED UNDER ISIN INE385W07034May 01, 2025
May 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 21, 2025
Apr 21, 2025Announcement under Regulation 30 (LODR)-Credit RatingApr 16, 2025
Apr 16, 2025DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015: COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD. RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SIApr 09, 2025
Apr 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Apr 01, 2025Board Meeting Outcome for OUTCOME OF BOARD MEETING: CESSATION AND APPOINTMENT OF INDEPENDENT DIRECTORSApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-AllotmentMar 26, 2025
Mar 26, 2025PRESS RELEASE REGARDING COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS SAS. RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS FOR ITS SAINT-BEAUZIRE SITE FRANCEMar 24, 2025
Mar 24, 2025DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015: COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS SAS. RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS FOR ITS SAINMar 19, 2025
Mar 19, 2025Closure of Trading WindowMar 19, 2025
Mar 19, 2025Board Meeting Outcome for BOARD APPROVES ISSUE OF RATED LISTED SENIOR SECURED REDEEMABLE TAXABLE NON-CONVERTIBLE DEBENTURES AGGREGATING UP TO RS. 50 CRORESMar 12, 2025
Mar 12, 2025Board Meeting Intimation for Consideration And Approval Of The Proposal Of Fund Raising By Way Of Issuance Of Non-Convertible Debentures By Way Of Private Placement Subject To Such Regulatory Or Statutory Approvals As May Be RequiredMar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Feb 12, 2025Integrated Filing (Financial)Feb 12, 2025
Feb 12, 2025Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2024Feb 12, 2025
Feb 12, 2025UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2024Feb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Board Meeting Intimation for Considering Take On Record And Approve The Un-Audited Financial Results Of The Company For The Third Quarter Ended On 31St December 2024Feb 08, 2025
Feb 08, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJan 31, 2025
Jan 31, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 10, 2025
Jan 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 10, 2025
Jan 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Jan 07, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 31, 2024
Dec 31, 2024Announcement under Regulation 30 (LODR)-CessationDec 14, 2024
Dec 14, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 20, 2024
Nov 20, 2024Announcement under Regulation 30 (LODR)-Change in ManagementNov 19, 2024
Nov 19, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2024
Nov 14, 2024Announcement under Regulation 30 (LODR)-Investor PresentationNov 14, 2024
Nov 14, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateNov 13, 2024
Nov 13, 2024Board Meeting Outcome for OUTCOME OF BOARD MEETING ALONGWITH UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30/09/2024Nov 13, 2024
Nov 13, 2024OUTCOME OF BOARD MEETING ALONGWITH UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30/09/2024Nov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 11, 2024
Nov 11, 2024Board Meeting Intimation for Considering, Take On Record And Approve The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September, 2024Nov 07, 2024
Nov 07, 2024Technical Indicators
RSI(14)
Neutral 76.44
ATR(14)
Less Volatile 11.73
STOCH(9,6)
Overbought 90.04
STOCH RSI(14)
Overbought 93.71
MACD(12,26)
Bullish 7.66
ADX(14)
Strong Trend 31.52
UO(9)
Bearish 68.94
ROC(12)
Uptrend And Accelerating 36.89
WillR(14)
Overbought -9.91
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 HSBC Flexi Cap Fund Direct-Growth | 1476000 | 0.61% | -0.10% | -0.09% | Apr 2025 | |
 Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth | 187974 | 0.18% | -0.03% | -0.03% | Apr 2025 | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 916 | 0.10% | -0.01% | -0.01% | Apr 2025 | |
 Angel One Nifty Total Market Index Fund Direct - Growth | 114 | 0.01% | 0.00% | 0.01% | Apr 2025 | |
| Bandhan Nifty Total Market Index Fund Direct-Growth | 129 | 0.01% | 0.00% | 0.00% | Apr 2025 | |
 Groww Nifty Total Market Index Fund Direct - Growth | 955 | 0.01% | 0.00% | 0.00% | Apr 2025 | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 132 | 0.01% | 0.00% | 0.00% | Apr 2025 | |
 Quant Value Fund Direct - Growth | 0 | 0.00% | 0.00% | 0.00% | Apr 2025 | |
 Samco Active Momentum Fund Direct - Growth | 0 | 0.00% | 0.00% | 0.00% | Apr 2025 |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
